Neurocrine Biosciences (NBIX)
(Delayed Data from NSDQ)
$137.76 USD
-1.21 (-0.87%)
Updated Apr 25, 2024 04:00 PM ET
After-Market: $137.75 -0.01 (-0.01%) 7:58 PM ET
2-Buy of 5 2
C Value A Growth F Momentum C VGM
Income Statements
Fiscal Year end for Neurocrine Biosciences, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 1,887 | 1,489 | 1,134 | 1,046 | 788 |
Cost Of Goods | 40 | 23 | 14 | 10 | 7 |
Gross Profit | 1,847 | 1,466 | 1,119 | 1,036 | 781 |
Selling & Adminstrative & Depr. & Amort Expenses | 1,597 | 1,217 | 1,017 | 873 | 708 |
Income After Depreciation & Amortization | 251 | 249 | 103 | 163 | 72 |
Non-Operating Income | 86 | -28 | 25 | -24 | 6 |
Interest Expense | 5 | 7 | 26 | 33 | 32 |
Pretax Income | 332 | 214 | 101 | 107 | 47 |
Income Taxes | 82 | 59 | 12 | -301 | 10 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | 250 | 155 | 90 | 407 | 37 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | 250 | 155 | 90 | 407 | 37 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | 255 | 266 | 131 | 193 | 98 |
Depreciation & Amortization (Cash Flow) | 4 | 17 | 28 | 30 | 26 |
Income After Depreciation & Amortization | 251 | 249 | 103 | 163 | 72 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 101.00 | 98.90 | 97.90 | 97.80 | 95.70 |
Diluted EPS Before Non-Recurring Items | 2.47 | 1.56 | 0.92 | 4.16 | 0.39 |
Diluted Net EPS (GAAP) | 2.47 | 1.56 | 0.92 | 4.16 | 0.39 |
Fiscal Year end for Neurocrine Biosciences, Inc falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 515.20 | 498.80 | 452.70 | 420.40 |
Cost Of Goods | NA | 8.50 | 11.20 | 11.50 | 8.50 |
Gross Profit | NA | 506.70 | 487.60 | 441.20 | 411.90 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 356.40 | 346.40 | 367.60 | 526.10 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | 150.30 | 141.20 | 73.60 | -114.20 |
Non-Operating Income | NA | 49.00 | -24.50 | 49.30 | 12.00 |
Interest Expense | NA | 1.10 | 1.10 | 1.30 | 1.10 |
Pretax Income | NA | 198.20 | 115.60 | 121.60 | -103.30 |
Income Taxes | NA | 50.50 | 32.50 | 26.10 | -26.70 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | 147.70 | 83.10 | 95.50 | -76.60 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | 147.70 | 83.10 | 95.50 | -76.60 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 102.30 | 101.10 | 100.20 | 97.10 |
Diluted EPS Before Non-Recurring Items | NA | 1.44 | 0.82 | 0.95 | -0.79 |
Diluted Net EPS (GAAP) | NA | 1.49 | 0.82 | 0.95 | -0.79 |